Investment
Features
FeesSafety
Academy
More
Pluang+

LSB Industries outperforms peers with strong margin growth and attractive valuation in nitrogen chemicals sector

Market News
27 May 2026
Seeking Alpha
View Source
Bullish
LSB Industries outperforms peers with strong margin growth and attractive valuation in nitrogen chemicals sector

LSB Industries, a leading U.S. ammonia and nitrogen chemical producer, has outperformed its material sector peers and the Russell 2000 index this year. The company is benefiting from a potential 900 basis points margin expansion driven by strong pricing, higher-value products, cost-plus contracts, and process improvements. Despite this, LSB trades at a forward EV/EBITDA multiple significantly below its five-year average and sector peers, offering a 7% free cash flow yield and substantial buyback capacity. Risks include fertilizer affordability issues in the U.S., renewed urea exports from China, and the potential expiration of a Stockholder Rights Plan in 2026.

More News

Copper explorers in British Columbia use electrical surveys to identify promising drill targets amid rising copper prices.

Copper explorers in British Columbia use electrical surveys to identify promising drill targets amid rising copper prices.

Copper exploration in British Columbia is increasingly relying on induced polarization (IP) geophysical surveys, which measure electrical chargeability and resistivity in rocks to identify sulphide mineralization associated with copper deposits. Gold...

Market News
Bullish
35 minutes ago
S&P 500 rises 30.6% in first 20 months of Trump's second term, nearing first term gains.

S&P 500 rises 30.6% in first 20 months of Trump's second term, nearing first term gains.

The S&P 500 index has increased by 30.6% during the first 20 months of Donald Trump's second presidential term, slightly surpassing the 28.5% gain recorded in the same period of his first term. This comparison is significant for investors as it provi...

Market News
Neutral
1 hour ago
Citigroup raises Krystal Biotech price target on Vyjuvek sales and promising KB113 trial results

Citigroup raises Krystal Biotech price target on Vyjuvek sales and promising KB113 trial results

Citigroup increased its price target for Krystal Biotech to $416 from $386, citing strong Q2 revenue of $119.2 million from its approved product Vyjuvek and encouraging early clinical data for KB113, a treatment for basal cell carcinomas in Gorlin sy...

Analyst Insights
Bullish
1 hour ago
Bank7 beats Q3 earnings estimates but revenue dips; merger with Century Financial set to close soon

Bank7 beats Q3 earnings estimates but revenue dips; merger with Century Financial set to close soon

Bank7 Corp. reported Q3 2026 earnings of $1.06 per share, slightly beating analyst estimates, while revenue of $23.37 million fell short and declined year-over-year. Despite lower revenue and earnings compared to last year, the bank continues to grow...

Company Fundamentals
Neutral
1 hour ago
Scotiabank raises Targa Resources price target to $319, citing strong momentum and a $1.25 dividend.

Scotiabank raises Targa Resources price target to $319, citing strong momentum and a $1.25 dividend.

Scotiabank increased its price target for Targa Resources to $319 from $314, indicating a potential 12.7% upside from the current share price of around $283. Targa Resources, a key player in the midstream energy sector, is recognized as a top momentu...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App